| Efficacy of intravenous infusion of doripenem. | |
| | |
MedLine Citation:
|
PMID: 19619018 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Initial treatment of nosocomial pneumonia (NP), including ventilator-associated pneumonia (VAP), is usually empirical. The use of a broad-spectrum antibiotic regimen to treat NP-VAP that is active against suspected multidrug-resistant pathogens maximizes the likelihood of a favorable outcome. In a post hoc analysis of pooled data from 2 prospective, randomized, open-label, phase 3 NP-VAP trials, doripenem, a new broad-spectrum carbapenem with antipseudomonal activity, demonstrated noninferiority to standard comparator regimens (imipenem and piperacillin-tazobactam) with regard to clinical and microbiological outcomes. In subgroup analyses, doripenem continued to show noninferiority to the comparator drugs in achieving clinical and microbiological cures in populations at high risk of multidrug-resistant infection, such as patients with late-onset VAP (defined as patients who develop VAP >5 days after intubation) or those with NP-VAP caused by Pseudomonas aeruginosa or complicated by bacteremia. Overall, the clinical data indicate that doripenem has the potential to be an important option in the treatment of NP, including VAP. |
| | |
Authors:
|
Marcos I Restrepo |
Related Documents
:
|
11284938 - Chloramphenicol treatment for vancomycin-resistant enterococcus faecium bacteremia. 3717938 - Aztreonam treatment of gram-negative septicemia. 11200708 - Intravenous followed by oral ofloxacin in the treatment of community acquired lower res... 2391738 - Ciprofloxacin compared with doxycycline for nongonococcal urethritis. ineffectiveness a... 12975198 - Traumatic anterior shoulder dislocation in adolescents. 15519198 - Early hemofiltration improves survival in post-cardiotomy patients with acute renal fai... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America Volume: 49 Suppl 1 ISSN: 1537-6591 ISO Abbreviation: Clin. Infect. Dis. Publication Date: 2009 Aug |
Date Detail:
|
Created Date: 2009-07-21 Completed Date: 2009-09-25 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9203213 Medline TA: Clin Infect Dis Country: United States |
Other Details:
|
Languages: eng Pagination: S17-27 Citation Subset: IM |
Affiliation:
|
University of Texas Health Science Center San Antonio and Audie L. Murphy Division, VERDICT/South Texas Veterans Health Care System, 7400 Merton Minter Blvd., San Antonio, TX 78229, USA. restrepom@uthscsa.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Carbapenems
/
administration & dosage*,
blood Cross Infection Humans Imipenem Infusions, Intravenous Penicillanic Acid / analogs & derivatives Piperacillin Pneumonia, Ventilator-Associated / drug therapy* |
| Chemical | |
Reg. No./Substance:
|
0/Carbapenems; 0/doripenem; 157044-21-8/piperacillin-tazobactam combination product; 61477-96-1/Piperacillin; 74431-23-5/Imipenem; 87-53-6/Penicillanic Acid |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: In vitro activity of doripenem.
Next Document: Safety of intravenous infusion of doripenem.